Opdivo can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. Fda approves opdivo for head and neck cancer pharmalive. Immunotherapy drug a gamechanger for head and neck cancer. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic rm squamous cell carcinoma of the head and neck scchn who had experienced progression within 6 months of platinumcontaining chemotherapy. Opdivo gentler than chemotherapy in head and neck cancer.
Pdf immunotherapy for recurrentmetastatic head and neck cancer. We report a rare case of pituitary disorder in a patients with head and neck cancer following nivolumab treatment. Its encouraging to see this drug, nivolumab, significantly improves survival for head and neck cancer. Nivolumab for recurrent squamouscell carcinoma of the head and neck. Prognostic markers in head and neck cancer patients treated with nivolumab article pdf available in cancers 1012. Nivolumab is produced in chinese hamster ovary cells by recombinant dna technology.
Aug 29, 2018 predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Nivolumab for recurrent carcinoma of head and neck s quamouscell carcinoma of the head and neck is a major cause of cancer associated illness and death, with more than 600,000 cases diagnosed annually worldwide. Nivolumab achieved a survival benefit compared with standard care in squamous cell carcinoma of the head and neck that progressed after platinumcontaining therapy. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Effectiveness of nivolumab in recurrent metastatic head. Nivolumab plus chemoradiation safe for advanced head, neck. More evidence on nivolumab is being collected, until september 2019. The patient was a man in his 50s with cancer of the tongue and. The food and drug administration fda approved nivolumab opdivo on november 10 for the treatment of squamous cell cancer of the head and neck scchn. Nivolumab is a programmed death1 inhibitor approved for the treatment of recurrentmetastatic squamous cell carcinoma of the head and neck scchn postplatinum therapy. Opdivo nivolumab is indicated for the treatment of patients with locally advanced or metastatic. Nivolumab immunotherapy appeared safe and feasible to administer in conjunction with radiation and chemotherapy for patients with newly diagnosed local. Head and neck squamous cell carcinoma hnscc is a frequent tumour arising from.
This is the first report of an irae of nivolumab in the field of head and neck squamous cell cancer. Food and drug administration approved nivolumab opdivo injection, bristolmyers squibb company, for the treatment of patients with recurrent or metastatic. The food and drug administration fda approved nivolumab opdivo on november 10 for the treatment of squamous cell cancer of the head and neck scchn nivolumab is already approved for the treatment of several other cancers. Cnw health canada has approved opdivo nivolumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. For people with previously treated squamous cell carcinoma of the head and neck. The nccn guidelines panel for cervical cancer screening endorses the following guidelines for the prevention and early detection of cervical cancer. After this nice will decide whether or not to recommend it for use on the nhs and update the guidance.
Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. We report a case of pituitaryadrenal dysfunction to isolated adrenocorticotropic hormone acth deficiency as an irae of nivolumab in a patient treated for head and neck cancer. Head and neck cancer is the seventh most common cancer globally, with an estimated 400,000 to 600,000 new cases per year and 223,000 to 300,000 deaths per year. Efficacy and safety in checkmate 141 by prior cetuximab use. Nivolumab in patients with recurrent or metastatic. Evidencebased recommendations on nivolumab opdivo for squamous cell carcinoma scc of the head and neck in adults who have had platinumbased chemotherapy. Nivolumab confers significant os benefit in recurrent or. The drug is an option for people who have had platinumbased chemotherapy that wasnt effective enough. European commission approves bristolmyers squibbs opdivo. Head and neck cancer lymphoma, hodgkins liver cancer.
Immunotherapy in head and neck cancer swiss medical weekly. Opdivo has been approved in germany since june 2017 for the treatment of squamous cell carcinoma of the head and neck in adults. Increased overall survival with nivolumab albeit only 7. Nivolumab in patients with recurrent or metastatic squamous. These problems can sometimes become serious or life. Opdivo nivolumab is a prescription medicine used to treat people with head and neck cancer squamous cell carcinoma that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working. It is best to read this information with our general information about the type of cancer you have. This document is part of an overall hcp toolkit intended to assist providers in optimizing management of rm hnscc. Nivolumab vs investigators choice in recurrent or metastatic. In the case of permitted digital reproduction, please credit the national cancer institute as the source and link to the original nci product using the original products title. Pdf immune checkpoint inhibition in head and neck cancer.
Squamous cell carcinoma of the head and neck hnscc is the 9th leading cancer. Click on it to view the protocol title and study information. Health canada approves opdivo nivolumab for the treatment. Nivolumab improved survival for patients with head and neck. Squamous cell carcinomas of the head and neck include tumors in the following areas. May 22, 2017 monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. The pd1 inhibitor nivolumab is the only drug approved for. Head and neck squamous cell carcinoma hnscc is a frequent tumour arising. Nivolumab is already approved for the treatment of several other cancers. Nivolumab for treating squamous cell carcinoma of the head and neck after platinumbased chemotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Nivolumab is fda approved as monotherapy for patients with recurrent metastatic squamous cell carcinoma of the head and neck rm hnscc with disease progression on or after a platinumbased therapy. Recurrent or metastatic head and neck cancer remains an area of high unmet medical need.
Introduction the prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. Nivolumab in patients with recurrent or metastatic squamous cell. Endogenous igg4 is known to cross the placental barrier, particularly during the third trimester. Os benefit was observed with nivolumab irrespective of pdl1 expression and hpv status. In this randomized, openlabel, phase 3 trial, we assigned, in a 2.
These cancers usually develop in the squamous cells which line the moist tissues in the head and neck, and are often curable if diagnosed at an early stage. For more information on immune therapy, click here. The immunotherapy opdivo nivolumab is less aggressive than standardofcare chemotherapy for patients with recurrent or metastatic head and neck cancer, and has less of an impact on patients quality of life, according to a major phase 3 trial. Evidencebased recommendations on nivolumab opdivo for squamous cell carcinoma of the head and neck in adults is this guidance up to date. Several payment sources exist for cancer drugs in ontario, depending on the drug, disease indication, and how and where it is delivered. Nivolumab for squamouscell cancer of head and neck.
There were an estimated 1,026 deaths from head and neck cancer last year. An estimated 560,000 cases of head and neck cancer affected patients globally in 2016, and in the u. Media release consumer media head and neck cancer patients. Nivolumab for recurrent squamouscell carcinoma of the head. Nctn head and neck cancer trials portfolio open as of 3162020 each far right box includes the nctn protocol number with a hyperlink to the associated clinicaltrials. Nivolumab, ipilimumab, and radiation therapy in treating.
Opdivo is a medicine that may treat your melanoma, lung cancer, kidney cancer, blood cancer, or head and neck cancer by working with your immune system. Immune checkpoint inhibitor toxicity in head and neck cancer. Oct, 2016 catherine pickworth, of cancer research uk london, uk, said. Fda approves nivolumab for head and neck cancer national. Nivolumab for recurrent squamouscell carcinoma of the.
It refers to many different cancers which affect the head and neck, such as mouth and throat cancer. Conclusions among patients with platinumrefractory, recurrent squamouscell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, singleagent therapy. Before nivolumab can be used routinely to treat head and neck cancer patients it will need to be approved for use on the nhs. Please see indication and important safety information.
Further evaluations of nivolumab nivo versus investigators choice ic chemotherapy for recurrent or metastatic rm squamous cell carcinoma of the head and neck hnscc. A trial looking at nivolumab for head and neck cancer. The pd1 inhibitor nivolumab is the only drug approved. Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Bmy today announced that the european commission ec has approved opdivo nivolumab as monotherapy for the treatment of squamous cell cancer of the head and neck scchn in adults progressing on or after platinumbased therapy. Common nivolumab starting doses for head and neck cancer. This case was reported in accordance with the principles of the declaration of helsinki.
In addition, patients are eligible for nivolumab or pembrolizumab. Please note that the guidelines listed are acrobat pdf files. A case of nivolumabinduced hypopituitarism in a head and. Squamous cell carcinoma of the head and neck scchn opdivo. Unexpected response to nivolumab in a fast progress or head. Checkmate 141, a pivotal phase 3 opdivo nivolumab head. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Neoadjuvant nivolumab with or without ipilimumab induces.
Patients with platinumrefractory head and neck cancer had significantly longer survival with nivolumab treatment than with standard, singleagent therapy. Window of opportunity trial of nivolumab and tadalafil in. That is head and neck cancer that has come back or spread to another part of the body. Nov 18, 2016 those with platinumrefractory recurrent squamouscell carcinoma of the head and neck about 70% of such cancers j clin oncol 2015. This new approval is for the use of nivolumab in patients with scchn that has progressed during chemotherapy with a. This is the first time an agent has shown a survival benefit in this group of patients, and nivolumab seems to represent a new standard of care in this setting. The society for immunotherapy of cancer consensus statement on. Oct 09, 2016 immunotherapy drug a gamechanger for head and neck cancer this article is more than 3 years old nivolumab found to extend lives of relapsed patients who had run out of therapy options. Clinical trial results squamous cell carcinoma of the head. Pituitaryadrenal dysfunction caused by nivolumab for head. Giving nivolumab and tadalafil may work better in treating patients head and neck squamous cell carcinoma. Jared weiss and josh bauml join grace to discuss updates relating to pembrolizumab, nivolumab and and pdl1 markers for head and neck cancers. Squamous cell cancer of the head and neck scchn opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinumbased therapy see section 5.
Individual doses may vary based upon your doctors recommendation, or drug availability. Immunotherapy for recurrentmetastatic head and neck cancer. The vast majority of these cancers are squamous cell carcinomas. Predictive biomarkers for response to nivolumab in head. Nivolumab advanced melanoma unresectable or metastatic melanoma nivolumab advanced or metastatic nonsmall cell lung cancer nivolumab plus ipilimumab advanced melanoma unresectable or metastatic melanoma nivolumab recurrent or metastatic squamous cell carcinoma of the head and neck, which is platinum resistant or refractory nivolumab plus ipilimumab metastatic renal cell. Patients who fail to respond to standar d chemotherapy have a poor prognosis5,6. Head and neck squamous cell carcinoma hnscc is a relatively common. Bc cancer protocol summary for palliative therapy for. Apr 16, 2018 chicago nivolumab continued to confer a significant os benefit compared with investigators choice of therapy among patients with recurrent or metastatic head and neck squamous cell.
Radiation therapy uses high energy xrays to kill tumor cells and shrink tumors. Nivolumab for recurrent head and neck cancer improves. Nivolumab is a fully human igg4 monoclonal antibody known as a programmed cell death 1 pd1 immune checkpoint inhibitor. Nctn head and neck cancer trials portfolio open as of 3162020. Post surgical resection, pt3 4nm0 or pt12n0m0 with positive margin. Squamous cell carcinoma of the head and neck scchn. Based on its mechanism of action, fetal exposure to nivolumab may increase the. In 2016, based on check mate 141 trial nivolumab was approved by. Nivolumab in squamous cell carcinoma of the head and neck. Listing a study does not mean it has been evaluated by the u. Nivolumab in combination with ipilimumab for recurrent or.
Catherine pickworth, of cancer research uk london, uk, said. The european commission ec has approved nivolumab opdivo, bristolmyers squibb for the treatment of squamous cell cancer of the head and neck scchn in. Cancers that are known as head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces inside the head and neck, such as inside the mouth and the throat. The median survival in most series is 6 to 15 months depending on patient and diseaserelated factors. The specific site of disease, stage, and pathologic findings guide treatment eg, the appropriate surgical procedure, radiation targets, dose and fractionation, indications for systemic therapy. The pd1 pathway is an immune system checkpoint that may be exploited by tumour cells to. Checkmate 141, a pivotal phase 3 opdivo nivolumab head and neck cancer trial, stopped early. Tadalafil may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Head and neck squamous cell carcinoma hnscc is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite. Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. Nivolumab improved survival for patients with head and. Combining radiation and immune checkpoint blockade in the. Nccn guidelines with nccn evidence blocks very advanced head and neck cancer about nccn evidence blocks. This new approval is for the use of nivolumab in patients with scchn that has progressed during chemotherapy with a platinumbased drug or that has recurred or.
Pdf prognostic markers in head and neck cancer patients. Predictive biomarkers for response to nivolumab in head and. In the firstline setting for recurrentmetastatic scchn, cetuximab as part of the platinumbased extreme regimen is a common treatment option. The incidence of pituitary disorders, especially nivolumab induced pituitary disorders, is low 2,3. Neoadjuvant nivolumab with or without ipilimumab appeared effective and safe for patients with resectable oral cavity cancer, according to results of a randomized phase 2 study presented at. Jnccn journal of the national comprehensive cancer network. Original article from the new england journal of medicine nivolumab for recurrent squamouscell carcinoma of the head and neck. This trial compared nivolumab with standard treatment. Food and drug administration fda for patients with metastatic or recurrent squamous cell carcinoma of the head and neck scchn following progression on platinumbased therapy. Nivolumab for head and neck cancer aim with immunotherapy.
1184 296 1211 956 1113 450 550 897 972 674 1301 241 125 417 140 823 1334 772 292 862 1477 832 1458 721 508 1118 1015 778 1409 791 1139 1125 1170 597 1415 55 1225 1216 497 842 352 597 1122 949 617 1148 1444